Ovarian Cancer in the Age of Precision Medicine

Guest Editor:

Dr. Alicia A. Tone
Ovarian Cancer Canada, Toronto, ON M5A 1E3, Canada

Deadline for manuscript submissions:
30 August 2024

Message from the Guest Editor

Dear Colleagues,

Ovarian cancer remains the most fatal gynecologic malignancy, with no effective screening modalities or diagnostic tests. This Special Issue will focus on the progress, challenges, and promise of omics to enable precision medicine for individuals with all types of ovarian cancer and how advances in precision medicine along the entire care continuum are needed to improve patient outcomes.

In this Special Issue, research areas may include (but are not limited to) the following:

- New samples, technologies, and/or approaches for early detection, most notably for high-grade serous ovarian/tubal/peritoneal cancer;
- Targeted prevention strategies based on lifetime risk of ovarian cancer;
- Novel precision treatments for less common types of ovarian cancer;
- Understanding and overcoming resistance to targeted treatments;
- Using omics to increase the efficacy of immune-based treatments in ovarian cancer;
- Patient engagement in basic, preclinical, and clinical research investigating precision medicine strategies;
- Novel approaches for personalized survivorship.

I look forward to receiving your contributions.

Dr. Alicia A. Tone

mdpi.com/si/175718

Special Issue